Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
暂无分享,去创建一个
C. Schiffer | T. Rana | S. Anjum | Akbar Ali | M.N.L. Nalam | H. Cao | G. Reddy
[1] B. Kuhn,et al. A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.
[2] Michael K. Gilson,et al. Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance , 2010, Journal of Virology.
[3] Youcef Mehellou,et al. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.
[4] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[5] S. Hammer,et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[6] Hong Cao,et al. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. , 2008, Journal of the American Chemical Society.
[7] Robert W Shafer,et al. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. , 2008, AIDS reviews.
[8] Tony Vangeneugden,et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. , 2008, AIDS research and human retroviruses.
[9] M. Youle. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. , 2007, The Journal of antimicrobial chemotherapy.
[10] Akbar Ali,et al. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. , 2007, Journal of medicinal chemistry.
[11] Jonathan M. Schapiro,et al. Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir , 2006, Journal of Virology.
[12] Dirk Jochmans,et al. TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[13] Celia A Schiffer,et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. , 2005, Journal of medicinal chemistry.
[14] N. Ford,et al. HIV drug resistance. , 2004, The New England journal of medicine.
[15] R. Zeldin,et al. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.
[16] Irene T. Weber,et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[17] Richard J Morris,et al. ARP/wARP's model-building algorithms. I. The main chain. , 2002, Acta crystallographica. Section D, Biological crystallography.
[18] Celia A Schiffer,et al. Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.
[19] Joseph Quinn,et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.
[20] C. Schiffer,et al. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. , 2000, Journal of molecular biology.
[21] Christos J. Petropoulos,et al. A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.
[22] K D Watenpaugh,et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. , 1998, Journal of medicinal chemistry.
[23] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[24] R. Hogg,et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. , 1998, JAMA.
[25] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[26] A. D. Rodrigues,et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir , 1997, Antimicrobial agents and chemotherapy.
[27] S. J. Brickner,et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. , 1996, Journal of medicinal chemistry.
[28] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[29] J Kuriyan,et al. Rigid protein motion as a model for crystallographic temperature factors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[30] Gary T. Wang,et al. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. , 1990, Science.
[31] W. Greco,et al. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. , 1979, The Journal of biological chemistry.
[32] K. N. Trueblood,et al. On the rigid-body motion of molecules in crystals , 1968 .
[33] T. Cihlar,et al. Current status and challenges of antiretroviral research and therapy. , 2010, Antiviral research.
[34] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.